Suppr超能文献

口服胰岛素治疗诱导产生的胰岛素B链反应性CD4 +调节性T细胞,通过阻断致糖尿病效应T细胞的细胞因子分泌和胰腺浸润来预防1型糖尿病。

Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells.

作者信息

Bergerot I, Arreaza G A, Cameron M J, Burdick M D, Strieter R M, Chensue S W, Chakrabarti S, Delovitch T L

机构信息

Autoimmunity/Diabetes Group, The John P. Robarts Research Institute, London, Ontario, Canada.

出版信息

Diabetes. 1999 Sep;48(9):1720-9. doi: 10.2337/diabetes.48.9.1720.

Abstract

The mechanism of protection from type 1 diabetes conferred by regulatory T-cells induced by oral insulin treatment of NOD mice is not well understood. We demonstrate that oral insulin feeding of NOD mice induces the function of insulin B-chain reactive CD4+ regulatory T-cells, which compete with diabetogenic effector T-cells for the recognition of insulin in NOD.Scid recipient mice. These effector T-cells become deprived of interleukin (IL)-2 and interferon (IFN)-gamma and are unable to expand and migrate to the pancreas. Type 1 diabetes-protective splenic regulatory T-cells secrete relatively little transforming growth factor (TGF)-beta1, suggesting that TGF-beta may not contribute to the inactivation of effector T-cells in NOD.Scid recipients. The observed preferential infiltration of insulin-reactive regulatory T-cells rather than effector T-cells in the pancreas results in a nondestructive insulitis that correlates with an increased intrapancreatic expression of macrophage inflammatory protein-1beta. Thus, oral insulin therapy overcomes a deficiency in regulatory T-cells and protects against type 1 diabetes by inducing insulin B-chain reactive regulatory T-cells to block cytokine secretion and migration of diabetogenic effector T-cells to the pancreas. Our data emphasize that continuous oral insulin feeding over a prolonged period is required to prevent type 1 diabetes.

摘要

口服胰岛素治疗非肥胖糖尿病(NOD)小鼠所诱导的调节性T细胞对1型糖尿病的保护机制尚未完全明确。我们证明,给NOD小鼠口服胰岛素可诱导胰岛素B链反应性CD4 +调节性T细胞的功能,这些调节性T细胞在NOD.Scid受体小鼠中与致糖尿病效应T细胞竞争识别胰岛素。这些效应T细胞会缺乏白细胞介素(IL)-2和干扰素(IFN)-γ,并且无法扩增和迁移至胰腺。1型糖尿病保护性脾调节性T细胞分泌相对较少的转化生长因子(TGF)-β1,这表明TGF-β可能对NOD.Scid受体中效应T细胞的失活没有作用。观察到胰岛素反应性调节性T细胞而非效应T细胞在胰腺中的优先浸润导致了一种非破坏性胰岛炎,这与胰腺内巨噬细胞炎性蛋白-1β表达增加相关。因此,口服胰岛素疗法克服了调节性T细胞的缺陷,并通过诱导胰岛素B链反应性调节性T细胞来阻断致糖尿病效应T细胞的细胞因子分泌和向胰腺的迁移,从而预防1型糖尿病。我们的数据强调,需要长期持续口服胰岛素来预防1型糖尿病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验